prikaz prve stranice dokumenta Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
  Preuzmi
PDF 386.56 KB
Znanstveni rad - Izvorni znanstveni rad
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer, 11 (2023), 4; e006406. https://doi.org/10.1136/jitc-2022-006406
Penack, Olaf; Peczynski, Christophe; Koenecke, Christian; Polge, Emmanuelle; Kuhnl, Andrea; Fegueux, Nathalie; Daskalakis, Michael; Kröger, Nicolaus; Dreger, Peter; Besley, Caroline; Schanz, Urs; Bloor, Adrian; Ganser, Arnold; Forcade, Edouard; Corral, Lucia López; Passweg, Jakob R; Novak, Urban; Moiseev, Ivan; Schoemans, Hélène; Basak, Grzegorz W; Chabannon, Christian; Sureda, Anna; Averbuch, Dina; Glass, Bertram; de la Camara, Rafael; Perić, Zinaida Više autora...

Citirajte ovaj rad

Penack, O., Peczynski, C., Koenecke, C., Polge, E., Kuhnl, A., Fegueux, N. ... Perić, Z. (2023). Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. Journal for ImmunoTherapy of Cancer, 11. (4). doi: 10.1136/jitc-2022-006406

Penack, Olaf, et al. "Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party." Journal for ImmunoTherapy of Cancer, vol. 11, br. 4, 2023. https://doi.org/10.1136/jitc-2022-006406

Penack, Olaf, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Andrea Kuhnl, Nathalie Fegueux, Michael Daskalakis, et al. "Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party." Journal for ImmunoTherapy of Cancer 11, br. 4 (2023). https://doi.org/10.1136/jitc-2022-006406

Penack, O., et al. (2023) 'Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party', Journal for ImmunoTherapy of Cancer, 11(4). doi: 10.1136/jitc-2022-006406

Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, i sur.. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. Journal for ImmunoTherapy of Cancer [Internet]. 04.2023. [pristupljeno 29.11.2024.];11(4). doi: 10.1136/jitc-2022-006406

O. Penack, et al., "Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party", Journal for ImmunoTherapy of Cancer, vol. 11, br. 4, Travanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:867008. [Citirano: 29.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:867008
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
AutorOlaf Penack
AutorChristophe Peczynski
AutorChristian Koenecke
AutorEmmanuelle Polge
AutorAndrea Kuhnl
AutorNathalie Fegueux
AutorMichael Daskalakis
AutorNicolaus Kröger
AutorPeter Dreger
AutorCaroline Besley
AutorUrs Schanz
AutorAdrian Bloor
AutorArnold Ganser
AutorEdouard Forcade
AutorLucia López Corral
AutorJakob R Passweg
AutorUrban Novak
AutorIvan Moiseev
AutorHélène Schoemans
AutorGrzegorz W Basak
AutorChristian Chabannon
AutorAnna Sureda
AutorDina Averbuch
AutorBertram Glass
AutorRafael de la Camara
AutorZinaida Perić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
We investigated the incidence and outcome of anti-CD19 chimeric antigen receptor (CAR) T-cells-associated Common Terminology Criteria for Adverse Events (CTCAE) ≥grade 3 cytopenia. In the EBMT CAR-T registry, we identified 398 adult patients with large B-cell lymphoma who had been treated with CAR-T-cells with axicel (62%) or tisacel (38%) before August 2021 and had cytopenia status documented for the first 100 days. Most patients had received two or three previous lines of therapy, however, 22.3% had received four or more. Disease status was progressive in 80.4%, stable in 5.0% and partial/complete remission in 14.6%. 25.9% of the patients had received a transplantation before. Median age was 61.4 years (min–max; IQR=18.7–81; (52.9–69.5)). The cumulative incidence of ≥grade 3 cytopenia was 9.0% at 30 days (95% CI (6.5 to 12.1)) and 12.1% at 100 days after CAR T-cell infusion (95% CI (9.1 to 15.5)). The median time from CAR-T infusion to cytopenia onset was 16.5 days (min–max; IQR=1–90; (4–29.8)). Grade 3 and grade 4 CTCAE cytopenia occurred in 15.2% and 84.8%, respectively. In 47.6% there was no resolution. Severe cytopenia had no significant impact on overall survival (OS) (HR 1.13 (95% CI 0.74 to 1.73), p=0.57). However, patients with severe cytopenia had a poorer progression-free survival (PFS) (HR 1.54 (95% CI 1.07 to 2.22), p=0.02) and a higher relapse incidence (HR 1.52 (95% CI 1.04 to 2.23), p=0.03). In those patients who developed severe cytopenia during the first 100 days (n=47), OS, PFS, relapse incidence and non-relapse mortality at 12 months after diagnosis of severe cytopenia were 53.6% (95% CI (40.3 to 71.2)), 20% (95% CI (10.4 to 38.6)), 73.5% (95% CI (55.2 to 85.2)) and 6.5% (95% CI (1.7 to 16.2)), respectively. In multivariate analysis of severe cytopenia risk factors, only year of CAR-T infusion (HR=0.61, 95% CI (0.39 to 0.95), p=0.028) and total number of treatment lines before CAR-T infusion (one or two lines vs three or more, HR=0.41, 95% CI (0.21 to 0.83), p=0.013) had a significant positive association with the incidence of cytopenia. Other factors, such as previous transplantation, disease status at time of CAR-T, patient age and patient sex, had no significant association. Our data provide insight on frequency and clinical relevance of severe cytopenia after CAR T-cell therapy in the European real-world setting.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal for ImmunoTherapy of Cancer
Brojčani podacivol. 11, br. 4, e006406
e-ISSN2051-1426
DOIhttps://doi.org/10.1136/jitc-2022-006406
URN:NBNurn:nbn:hr:105:867008
Datum objave publikacije2023-04
URL dokumentahttps://jitc.bmj.com/lookup/doi/10.1136/jitc-2022-006406
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2023-11-24 10:49:21